Uli Rass
@u-rass.bsky.social
63 followers
57 following
13 posts
I do my science at the Genome Damage and Stability Centre at the University of Sussex in sunny Brighton.
Posts
Media
Videos
Starter Packs
Pinned
Uli Rass
@u-rass.bsky.social
· Sep 3
DNA2 enables growth by restricting recombination-restarted replication - Nature
DNA2 suppresses recombination-restarted replication and checkpoint activation at stalled forks, and its loss triggers recombination-dependent synthesis, checkpoint signalling and cell-cycle exit, high...
www.nature.com
Reposted by Uli Rass
Reposted by Uli Rass
Reposted by Uli Rass
Reposted by Uli Rass
Reposted by Uli Rass
Reposted by Uli Rass
The Guardian
@theguardian.com
· 14d
Huntington’s disease treated successfully for first time in gene therapy trial
UCL trialled hours-long surgical procedure to treat disease which causes dementia and paralysis
Huntington’s disease, a devastating degenerative illness that runs in families, has been treated successfully for the first time in a breakthrough gene therapy trial.
The disease, caused by a single gene defect, steadily kills brain cells leading to dementia, paralysis and ultimately death. Those with a parent with Huntington’s have a 50% chance of developing the disease, which until now has been incurable. Continue reading...
www.theguardian.com
Reposted by Uli Rass
Reposted by Uli Rass
Nature
@nature.com
· 14d
CRISPR activation for SCN2A-related neurodevelopmental disorders - Nature
Using SCN2A haploinsufficiency as a proof-of-concept, upregulation of the existing functional gene copy through CRISPR activation was able to rescue neurological-associated phenotypes in Scn2a haploinsufficient mice and human neurons.
go.nature.com
Reposted by Uli Rass
The Guardian
@theguardian.com
· 14d
UK is ‘worst country in Europe’ for drug prices, says Mounjaro maker
Eli Lilly CEO says Britain’s strict regime means it could miss out on new drugs being rolled out unless it pays more
*
Business live – latest updates
The chief executive of the pharmaceutical company Eli Lilly has said the UK is “probably the worst country in Europe” for drug prices, amid a row between the industry and government.
Dave Ricks said that the UK’s strict pricing regime, allowing it to pay less for drugs than other developed countries, means it would miss out on new drugs being rolled out if it did not raise prices and scrap a rebate scheme. Continue reading...
www.theguardian.com
Reposted by Uli Rass
Reposted by Uli Rass
Reposted by Uli Rass
Uli Rass
@u-rass.bsky.social
· 19d
Uli Rass
@u-rass.bsky.social
· 19d
Reposted by Uli Rass
Reposted by Uli Rass
Reposted by Uli Rass